# PHARMACEUTICAL 2026

## Bristol Myers Squibb CO
## Rank 108 of 178



# PHARMACEUTICAL 2026

## Bristol Myers Squibb CO
## Rank 108 of 178

Bristol Myers Squibb

The relative strengths and weaknesses of Bristol Myers Squibb CO are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Bristol Myers Squibb CO compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 56% points.The greatest weakness of Bristol Myers Squibb CO is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 112% points.

The company's Economic Capital Ratio, given in the ranking table, is 196%, being 34% points below the market average of 229%.

| Input Variable | Value in 1000 USD |
|---|---|
| Assets, Current | 29,390,000 |
| Cost of Goods Sold | 13,936,000 |
| Intangible Assets | 40,857,000 |
| Liabilities, Current | 23,417,000 |
| Liabilities, Non-Current | 47,893,000 |
| Other Assets | 12,248,000 |
| Other Compr. Net Income | -288,000 |
| Other Expenses | 9,984,000 |
| Other Liabilities | 223,000 |
| Other Net Income | 0 |
| Other Revenues | 48,194,000 |
| Property and Equipment | 7,543,000 |
| Research and Development | 9,951,000 |
| Selling, General and Administrative Expense | 7,267,000 |

| Output Variable | Value in 1000 USD |
|---|---|
| Assets | 90,038,000 |
| Liabilities | 71,533,000 |
| Expenses | 41,138,000 |
| Revenues | 48,194,000 |
| Stockholders Equity | 18,505,000 |
| Net Income | 7,056,000 |
| Comprehensive Net Income | 6,912,000 |
| BaseVar | 125,595,500 |
| ECR before LimitedLiability | 58% |
| Economic Capital Ratio | 196% |